1.
Zhonghua Nei Ke Za Zhi
; 61(7): 756-763, 2022 Jul 01.
Artigo
em Zh
| MEDLINE
| ID: mdl-35764558
RESUMO
In recent years, with the continuous in-depth research on the pathogenesis of rheumatism and the rapid development of biopharmaceutical technology, the development of targeted drugs for rheumatism is in full swing. In order to better standardize the diagnosis and treatment of rheumatism and the rational application of targeted drugs, the Chinese Rheumatology Association will introduce the targeted drugs for rheumatism that have been approved by the China National Medical Products Administration so far, and provide clinicians with standardized diagnosis and treatment reference.